Progress and challenges of confirmatory trials for cancer drugs granted conditional approval in China

被引：0
|
作者：
Luo, Xingxian [1 ]
Xu, Yang [2 ,3 ]
Du, Xin [4 ]
Lv, Xufeng [5 ]
Chen, Si [5 ]
Yang, Yue [2 ,3 ]
Huang, Lin [1 ]
Zhang, Xiaohong [1 ]
机构：
[1] Peking Univ, Dept Pharm, Peoples Hosp, Beijing, Peoples R China
[2] Tsinghua Univ, Sch Pharmaceut Sci, Beijing, Peoples R China
[3] Natl Med Prod Adm, Key Lab Innovat Drug Res & Evaluat, Beijing, Peoples R China
[4] Tsinghua Univ, Vanke Sch Publ Hlth, Beijing, Peoples R China
[5] Natl Med Prod Adm, Ctr Drug Evaluat, Beijing, Peoples R China
来源：
LANCET REGIONAL HEALTH-WESTERN PACIFIC | 2024年 / 52卷
基金：
中国国家自然科学基金;
关键词：
SURVIVAL; ONCOLOGY;
D O I：
10.1016/j.lanwpc.2024.101238
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页数：5
相关论文
共 7 条
  • [1] Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022
    Luo, Xingxian
    Du, Xin
    Huang, Lin
    Guo, Qixiang
    Lv, Xufeng
    Wang, Cen
    Liu, Haopeng
    Zhou, Yue
    Xue, Xuecai
    Li, Zhuangqi
    Liu, Jingwen
    Chow, Shein-Chung
    Yang, Yue
    ECLINICALMEDICINE, 2023, 63
  • [2] Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, 2020-2024
    Luo, Xingxian
    Du, Xin
    Lv, Xufeng
    Yang, Yue
    Zhang, Xiaohong
    Huang, Lin
    JAMA NETWORK OPEN, 2024, 7 (10) : e2439080
  • [3] Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework
    Jiao, Boshen
    PHARMACOECONOMICS, 2023, 41 (12) : 1617 - 1627
  • [4] Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness
    McPhail, Melanie
    Weiss, Emma
    Bubela, Tania
    FRONTIERS IN MEDICINE, 2022, 8
  • [5] Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency
    Maeda, H.
    Kurokawa, T.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 211 - 216
  • [6] Participation of African American Persons in Clinical Trials Supporting US Food and Drug Administration Approval of Cancer Drugs
    Al Hadidi, Samer
    Mims, Martha
    Miller-Chism, Courtney Nicole
    Kamble, Rammurti
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (04) : 320 - +
  • [7] Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price
    Michaeli, Julia Caroline
    Michaeli, Thomas
    Trapani, Dario
    Albers, Sebastian
    Dannehl, Dominik
    Wuerstlein, Rachel
    Michaeli, Daniel Tobias
    BREAST CANCER, 2024, 31 (06) : 1144 - 1155
1